C3 AI Explores Sale as Founder Steps Down Over Health Issues
Enterprise AI software provider C3 AI considers potential sale after founder Thomas Siebel's departure as CEO. Stock down 54% YTD amid financial struggles and leadership changes.
NOTRELOAD AI
Surgery Partners Stock Plunges 25% on Lowered Revenue Outlook
Surgery Partners shares hit five-year low after cutting full-year guidance due to weaker patient volumes and insurance payment trends in Q3 2025.
Opendoor’s Bold Move Against Short Sellers
Opendoor fights back against short sellers with tradable warrants, turning a massive stock loss into a record comeback.
H.C. Wainwright Raises Vera Therapeutics Price Target to $90 After ORIGIN 3 Data
Vera Therapeutics has submitted its application for atacicept, a potential breakthrough IgAN treatment that successfully reduced proteinuria in the Phase 3 ORIGIN 3 trial.
FDA Clears Path for Key Phase 3 Trial of Lacutamab in CTCL Treatment
Innate Pharma is moving forward with the TELLOMAK 3 trial for lacutamab in advanced cutaneous T-cell lymphomas (CTCL), including Sézary syndrome (SS) and Mycosis fungoides (MF).
Papa John's Nears $2.7B Private Takeover by TriArtisan Capital
Papa John's is nearing an all-cash deal to go private. TriArtisan Capital offered $65 per share, a nearly 58% premium, valuing the chain at $2.7B.